Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 157

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 157
---
 -COVIDprescriptions in the United States; and •attracting, hiring, and retaining qualified personnel. Alexander Zwyer, its Chief Executive Officer, and Eric Konofal, its Chief Scientific Officer, have interests that may be different from, or in addition to, the interests of its shareholders and the Company and Aexon may not have sufficient funds to continue or grow operations. Alexander Zwyer owns 35% of Aexon, and Eric Konofal owns 59% of Aexon. Mr. Konofal is the founder of Aexon, with which NLS has a license agreement, and also serves as the President of Aexon. Mr. Zwyer holds no board or executive position at Aexon Labs, Inc., or Aexon. Mr. Zwyer and Mr. Konofal may have interests in the transactions with Aexon that may be different from, or in addition to, the interests of its shareholders and that may create potential conflicts of interest. Each of NLS and Aexon expect to be required to obtain additional liquidity in order to fund operations through the approval of certain of each of the company’s products. Until each company can generate significant revenues, if ever, each company expects to satisfy its future cash needs through debt or equity financings. Each company cannot be certain that funding will be available to it on acceptable terms, if at all. If funds are not available, each company may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to each company’s products. NLS expects that it will need to raise substantial additional funding before NLS can expect to complete the development of Quilience or any other product candidate. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product candidate development efforts or other operations. As of December 31, 2024, NLS’s cash and cash equivalents were approximately $1.7 million, and NLS had a positive working capital of $1.4 million and an accumulated deficit of $74.4 million. Based upon its currently expected level of operating expenditures, NLS believes that its current cash on hand and access to existing financial arrangements 42 will not be sufficient to fund its projected operating requirements for a period of one year from the issuance of these financial statements included elsewhere in this proxy statement/prospectus. This